



Financial Tear Sheet


Corporate Profile

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ is a steroid in late-stage clinical development for the treatment of Ménière's disease. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. Multiple programs targeting sensorineural hearing loss including age-related hearing loss are in preclinical development. These programs involve the anatomical and functional restoration of ribbon synapses, protection of hair cells from chemotoxicity, and regeneration of hair cells.

Stock Performance

OTIC (Common Stock)

Exchange NASDAQ GS (US Dollar)
 Price **\$5.55**
 Change (%) **▲ 0.05 (0.91%)**
 Volume 843,035
 52 Week High \$21.15
 52 Week Low \$2.80
 Data as of 11/17/17 4:00 p.m. ET



Data Provided by Thomson Reuters

Recent Headlines & Events

- 11/08/17 - 4:13 p.m.
[Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 11/08/17 - 4:07 p.m.
[Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
11/08/17	10-Q
11/08/17	8-K

Primary IR Contact

E-mail: ir@otonomy.com